View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 27, 2011

Glenmark Completes Phase I Trial of Pain Drug

Glenmark Pharmaceuticals has successfully completed a Phase I trial of GRC 15300, a first-in-class TRPV3 inhibitor for the treatment of pain. The study was conducted in the UK and showed that the drug was well tolerated and had a good pharmacokinetic profile. The company said

By cms admin

Glenmark Pharmaceuticals has successfully completed a Phase I trial of GRC 15300, a first-in-class TRPV3 inhibitor for the treatment of pain.

The study was conducted in the UK and showed that the drug was well tolerated and had a good pharmacokinetic profile.

The company said it is planning to initiate clinical proof-of-concept studies in neuropathic pain.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology